CORIPHAR
ActiveFrom the official registers: KBO 37 annual accounts at the National Bank publications in the Belgian Official Gazette
Summary
CORIPHAR has been active since 1989 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €146,896 and a net result of €25,225. Equity has been stable since 2018 (±2.4% per year). Its solvency ranks better than 48% of 12,757 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.4% (very low).
Overview
Official details
KBO- Status
- Active since 04-04-1989 Normal situation
- Legal form
- Private limited company (pre-2019)
- Registered office
- Getestraat 81, 3300 Tienen
- Activity
- Retail sale of pharmaceutical products NACE 47730
- Establishment unit
- 2.049.649.986 3300 Tienen, since 01-10-1990
- Financial year end
- 31 December
- Peppol
- Reachable since 23-01-2026
Board and ownership
Board
- Apotheek TramstatieDirector · since 17-11-2008
Shareholders
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.4%
Annual accounts 2025
- Gross margin
- €55,990
- ▼ 29.4%
- Turnover
- ≈ €270,000
- estimated
- Profit
- €25,225
- ▼ 71.1%
- Equity
- €146,896
- =
- Total assets
- €425,689
- ▼ 20.2%
- Staff
- 0.3 FTE
- =
2025 accounts filed 28 days after the deadline
Filed on 28-08-2026at the National Bank
Score breakdownraises riskLast filed accounts filed 28 days late; 2 of the last 3 accounts lateSector: Retail trade (NACE 47)lowers riskFounded in 1989Liquidity: current ratio 1.97, cash €62,294Show the evidence
Checked score
Score 2025
83
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 49% of micro companies in retail trade (NACE 47)
Financial strength · tick: 2024
Strong
Solvency
60+7
equity 34.5% of total assets
Liquidity
43+3
short-term debt 49.7% · cash 14.6%
Profitability
76-13
return on assets 5.9%
Bankruptcy probability within 12 months
0.4%
Very low
0%0.5%1.5%4%10%≥ 25%
About 4 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
11-2024: 0.4%
12-2024: 0.4%● unchanged vs 11-2024
01-2025: 0.4%● unchanged vs 12-2024lowest value
02-2025: 0.4%● unchanged vs 01-2025
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025
06-2025: 0.4%● unchanged vs 05-2025
07-2025: 0.5%▲ +0.1 percentage points vs 06-2025
08-2025: 0.8%▲ +0.3 percentage points vs 07-2025
09-2025: 0.9%▲ +0.1 percentage points vs 08-2025
10-2025: 1.2%▲ +0.3 percentage points vs 09-2025highest value
11-2025: 0.5%▼ -0.7 percentage points vs 10-2025
12-2025: 0.5%● unchanged vs 11-2025
01-2026: 0.4%▼ -0.1 percentage points vs 12-2025
02-2026: 0.4%● unchanged vs 01-2026
03-2026: 0.4%● unchanged vs 02-2026
04-2026: 0.4%● unchanged vs 03-2026
05-2026: 0.5%▲ +0.1 percentage points vs 04-2026
06-2026: 0.4%▼ -0.1 percentage points vs 05-2026
07-2026: 0.4%● unchanged vs 06-2026
08-2026: 0.7%▲ +0.3 percentage points vs 07-2026
09-2026: 0.4%▼ -0.3 percentage points vs 08-2026
10-2026: 0.4%● unchanged vs 09-2026
Credit of up to €12,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 1.97 (1.74 in 2024), above the usual 1.5. Short-term debt is 49.7% and cash 14.6% of total assets. However, 65.5% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 50% of them on solvency, 42% on liquidity, 64% on profitability and 39% on growth.
The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 28 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
28 days late
2024
71 days late
2023
61 days late
2022
61 days late
2021
30 days late
2020
27 days late
2019
59 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 48 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 30 September (4 of the last 5 filed years within 31 days of that day).
Companies Code · seven monthsWhere today falls in the filing period
01-11-2026 today31-12-2026 year end31-07-2027 deadline
Key points
Documents
Annual accounts at the NBB
- Annual accounts 2025filed on 28-08-2026
- Annual accounts 2024filed on 10-10-2025
- Annual accounts 2023filed on 30-09-2024
- Annual accounts 2022filed on 30-09-2023
Acts in the Belgian Official Gazette
All publications in the Belgian Official GazetteArticles and registers
- Coordinated articles of associationnotaries' database
- Entry in the KBO registerKBO Public Search
Key facts about CORIPHAR
- What is the company number of CORIPHAR?
- The company number of CORIPHAR is 0437.150.690. The VAT number is the same number with BE in front: BE 0437.150.690.
- Where is CORIPHAR based?
- The registered office is at Getestraat 81, 3300 Tienen.Company details
- What does CORIPHAR do?
- According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
- What is the legal form of CORIPHAR?
- The legal form of CORIPHAR is Private limited company (pre-2019) (BVBA).
- When was CORIPHAR founded?
- CORIPHAR was founded on 04-04-1989.
- Is CORIPHAR still active?
- Yes, CORIPHAR is an active enterprise in the KBO register.
- How many employees does CORIPHAR have?
- CORIPHAR had an average of 0.3 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of CORIPHAR?
- The turnover in financial year 2025 is ≈ €270,000. This figure is estimated from the gross margin of €55,990 and 73 comparable companies (NACE 477). It probably lies between €130,000 and €390,000. In financial year 2021 turnover was €708,102.
- Is CORIPHAR profitable?
- In financial year 2025, CORIPHAR made a profit of €25,225.
- Where can I find the annual accounts of CORIPHAR?
- CORIPHAR filed 37 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
- When are the next annual accounts of CORIPHAR due?
- CORIPHAR must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Companies linked to CORIPHAR
Comparable companies
These companies have the same main activity as CORIPHAR: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €348,000 and €566,000, founded between 1984 and 1996.
| Company | Total assets | Gross margin |
|---|---|---|
| CORIPHAR Tienen | €425,689 | €55,990 |
| Apotheek Dawyndt Anzegem | €469,553 | €57,520 |
| APOTHEEK GLORIE Duffel | €402,512 | €49,495 |
| APOTHEEK VANDEVIVERE Sint-Lievens-Houtem | €348,318 | €55,456 |
| APOTHEEK JANSSEN Knokke-Heist | €398,271 | €43,763 |
| VAN DE PLAS PHARMA Sint-Genesius-Rode | €566,351 | €49,809 |
| STRYBOL TRUI APOTHEEK Brugge | €397,630 | €49,008 |
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.